- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Vanda Pharmaceuticals Announces New Senior Vice President
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) has named Gian Piero Reverberi the company’s new Senior Vice President, Acting Chief Commercial Officer and European General Manager.
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) has named Gian Piero Reverberi the company’s new Senior Vice President, Acting Chief Commercial Officer and European General Manager.
According to the press release:
Mr. Reverberi was previously Vanda’s Senior Vice President and European General Manager and replaces Tom Gibbs, Vanda’s former Senior Vice President and Chief Commercial Officer, who has resigned from Vanda to pursue a new opportunity.
“I would like to congratulate Gian Piero in his new role, and wish him much success as we continue to drive Vanda on a strong growth trajectory. I also would like to thank Tom for his leadership and significant contributions over the past year and wish him success as he pursues his next opportunity,” said Mihael H. Polymeropoulos MD, President and CEO, Vanda Pharmaceuticals.
Prior to joining Vanda, Mr. Reverberi served as Senior Vice President, International Specialty Pharma at Shire Pharmaceuticals, with responsibility for Shire’s specialty pharma business in EMEA, Canada, Australia, Japan, Asia Pacificand Latin America. In addition to his International Specialty Pharma responsibilities, from 2009-2013, Mr. Reverberi led Shire’s Internal Medicine Global Business Unit where his responsibilities included the management of the US Sales and Marketing teams. Prior to this position, he was General Manager, Italy at Shire. Before joining Shire, Mr. Reverberi spent 10 years with Eli Lilly in Italy and the U.S. where he held several commercial positions including Business Unit Director (Diabetes Care) in Italy, District Manager and Business Development Leader in the U.S. Earlier in his career, Mr. Reverberi held finance positions in the U.S. and Italy with both Eli Lilly and IBM. Mr. Reverberi received his degree in Economics and Business Administration from Sapienza University of Rome and a Master in Business Administration from SDA Bocconi in Milan.
Click here to read the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.